Φορτώνει......
Disease progression patterns of bevacizumab responders with recurrent malignant gliomas
Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Oncol Lett |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
D.A. Spandidos
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/ https://ncbi.nlm.nih.gov/pubmed/28927109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|